CKPT vs. LPTX, QURE, IMMP, ENTA, ATAI, NKTR, EPIX, ALDX, FHTX, and ELYM
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Leap Therapeutics (LPTX), uniQure (QURE), Immutep (IMMP), Enanta Pharmaceuticals (ENTA), Atai Life Sciences (ATAI), Nektar Therapeutics (NKTR), ESSA Pharma (EPIX), Aldeyra Therapeutics (ALDX), Foghorn Therapeutics (FHTX), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Leap Therapeutics received 119 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 68.72% of users gave Leap Therapeutics an outperform vote while only 66.28% of users gave Checkpoint Therapeutics an outperform vote.
Checkpoint Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.
Leap Therapeutics has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.
In the previous week, Checkpoint Therapeutics had 4 more articles in the media than Leap Therapeutics. MarketBeat recorded 5 mentions for Checkpoint Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.59 beat Checkpoint Therapeutics' score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Checkpoint Therapeutics has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Checkpoint Therapeutics presently has a consensus price target of $22.60, suggesting a potential upside of 1,095.77%. Leap Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 391.07%. Given Checkpoint Therapeutics' higher probable upside, equities research analysts clearly believe Checkpoint Therapeutics is more favorable than Leap Therapeutics.
Summary
Leap Therapeutics beats Checkpoint Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
